Oral Session: Pharmacology S93
Background: Schizophrenia is a chronic debilitating disorder which affects about 21 million people worldwide (WHO 2017) . Elevated pre-synaptic striatal dopamine synthesis capacity is a robust neurochemical alteration seen in patients with schizophrenia compared to controls, with a large effect size Cohen's d=0.79 (Howes et al., 2012) . Ketamine, a non-competitive N-methyl-D-aspartate receptor (NMDAR) antagonist induces psychotomimetic effects in healthy human (Krystal et al., 1994 , Stone et al., 2007 and exacerbates psychotic symptoms in patients with schizophrenia (Lahti et al., 1991) . For these reasons, it has been used to model the neurochemical alterations seen in schizophrenia such as dopaminergic overactivity (Usun et al., 2013 , Kokkinou et al., 2017 . However, the effect of sub-chronic ketamine on dopamine synthesis capacity in vivo is not known. Here we investigated the effect of sub-chronic ketamine on striatal dopamine synthesis capacity in vivo using Positron Emission Tomography (PET) imaging and on locomotor activity in the mouse. Moreover, via a chemogenetics approach (Roth 2016) we explored the role of midbrain dopamine neuron activity in mediating ketamine-induced effects. Methods: All procedures were conducted under licence in accordance with the UK Animals (Scientific Procedures) Act of 1986. Mice received a sub-anaesthetic dose of ketamine or an equivalent volume of saline for five consecutive days. Locomotor activity was assessed in the open field test. Moreover, mice received a dynamic 3,4-dihydroxy-6-[(18)F]-fluoro-Lphenylalanine Positron Emission Tomography (PET) scan to assess striatal dopamine synthesis capacity in vivo. Data were analysed using an extended Patlak graphical analysis approach (Walker et al., 2013) . Further midbrain dopamine neurons were transduced with an adeno-associated virus vector expressing Gi-coupled (hM4Di) inhibitory receptors under the control of the dopamine transporter (DAT) promoter in DATCre positive mice. Standard immunohistochemistry was used to label dopamine neurons and mCherry expression in dopamine neurons was confirmed using confocal microscopy. Two weeks following the stereotaxic injection of the viral construct, mice received clozapine N-oxide (CNO) to study the effects of inhibiting dopamine neuron firing on locomotor activity and striatal dopamine synthesis capacity in the sub-chronic ketamine model. Data were analysed by two-tailed independent samples t-tests, one-way ANOVA and repeated measures two-way ANOVA followed by Bonferroni post hoc tests where appropriate. p<0.05 was considered statistically significant. Results: Sub-chronic ketamine treatment significantly increased striatal dopamine synthesis capacity (p<0.05, effect size=1.2) and induced locomotor sensitization (p<0.01). hM4Di-mCherry viral construct was successfully transduced in midbrain dopamine neurons with over 98% specificity. Chemogenetic inhibition of midbrain dopamine neurons prevented the ketamine-induced elevation in striatal dopamine synthesis capacity (p<0.05, effect size= 0.64) and locomotor sensitization (p<0.05).
Discussion: Our data show that sub-chronic ketamine results in the elevation in striatal dopamine synthesis capacity and locomotor sensitization and that these effects require midbrain dopamine neuron activation. Furthermore, our data are in support of the hypothesis that NMDA receptor hypofunction on GABAergic interneurons leads to disinhibition of glutamatergic projections and subsequently increase in dopamine neuron activity and dopamine synthesis capacity in projection targets such as the striatum. Background: Antipsychotic drugs are effective in reducing the severity of psychotic symptoms both in the short and long term, and in reducing risk of relapse. However, some patients may develop a relapse of their psychotic symptoms despite continued antipsychotic treatment. Arguably, this phenomenon would be best studied in patients treated with long-acting injectable (LAI) formulations, where the dates of exposure can be confirmed, removing the potential confounder of non-adherence. The characterization of this phenomenon can add important knowledge about the intrinsic efficacy of antipsychotic drugs, potential mechanisms involved in the decrement of their efficacy, and the underlying pathophysiology of psychosis that is not modulated via primarily dopaminergic mechanisms. Despite the implications of this clinical phenomenon, research on breakthrough on antipsychotic maintenance medication (BAMM) in models not confounded by non-adherence has been limited. To date, little is known about the incidence and predictors of BAMM in clinical populations.
O7.2. BREAKTHROUGH ON ANTIPSYCHOTIC

Methods:
We extracted data from a cohort of individuals with a psychotic disorder who were initiated on their first LAI treatment between 2010 and 2015 in the injection clinic at The Zucker Hillside Hospital (New York, USA). We defined BAMM as hospitalization during the period of continuous treatment with LAI, which we used as the primary outcome. LAI treatment was considered continuous for each treatment episode if it was administered following the manufacturer's recommendations for the first 2 months, and until there was a delay in the administration that would have required additional oral supplementation according to the manufacturer instructions (typically >1.5 times the scheduled interval of administration). .25-19.40 ). We conducted a mutivariate Cox regression analysis for time to hospitalization and a sensitivity analysis comparing BAMM with individuals that completed 2 years of continuous treatment without being hospitalized and the results were consistent. Discussion: In a clinical cohort, a meaningful proportion of patients with a psychotic disorder treated with LAIs were hospitalized, despite confirmed continuous treatment. The median time to this event occurred about 7 months after onset of LAI treatment, suggesting that these patients had been stable and had reached steady state antipsychotic levels prior to hospitalization. Patients with a more active illness at the time of initiation of LAI treatment were more likely to relapse. These data suggest that more
